{"id":744022,"date":"2023-03-30T15:41:29","date_gmt":"2023-03-30T19:41:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/"},"modified":"2023-03-30T15:41:29","modified_gmt":"2023-03-30T19:41:29","slug":"investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/","title":{"rendered":"Investigation of Fulcrum Therapeutics, Inc. (FULC) Announced by Holzer &amp; Holzer, LLC"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ATLANTA, March  30, 2023  (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether Fulcrum Therapeutics, Inc. (\u201cFulcrum\u201d\u202for the \u201cCompany\u201d) (NASDAQ: FULC) complied with federal securities laws. On February 24, 2023, Fulcrum announced that \u201con February 23, 2023, the U.S. Food and Drug Administration (FDA) verbally informed the company that it has issued a full clinical hold regarding the Investigational New Drug (IND) application for FTX-6058.\u201d Following this announcement, the price of the Company\u2019s stock dropped.<\/p>\n<p align=\"justify\">If you purchased Fulcrum stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey Holzer, Esq. at\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qm8tKnp3GDM_shC4dxF90zzH33E-EeNAFT3vm7-rg_zA2RM48lPthpzF5LYpR4hsCwFn_8vI6X8oFMDGnBOYgFeHevl0Tdj7TJVoaDACJaI=\" rel=\"nofollow noopener\" target=\"_blank\"><u>cholzer@holzerlaw.com<\/u><\/a>\u202for Joshua Karr, Esq. at\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LCmdkv_axKd-Xs-NGGgxXwPJ8aNV--K8P58G1sG_JQs4wLu-9x7oMjJlwRXlwBZti7bQbnAEsMqbmSQz8d90xcjS3ryEFKOnqL28R6u0YXM=\" rel=\"nofollow noopener\" target=\"_blank\"><u>jkarr@holzerlaw.com<\/u><\/a>, call our toll-free number at (888) 508-6832, or visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QizQWnGNwjN20y5CO04VU2AL66URqqOPM9EHWpg8mZaDUzDxRV2eBW8ha1BRPZYJaYag417vQly6f96pqZsJSjuq1E5_XijNZXgWQxdldLnojW2e0prnk3Teiss4ZhED\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/holzerlaw.com\/case\/fulcrum\/<\/u><\/a> to discuss your legal rights.<\/p>\n<p align=\"justify\">Holzer &amp; Holzer, LLC, an ISS top rated securities litigation law firm for 2021 &amp; 2022, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer &amp; Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.\u202fMore information about the firm is available through its website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GD8d7zdJRonSVy7EEXX4ijSOspGiz5_V9jP9wOiQ5Bfwg2qBYm35lhhXyIF2J7e2cqGrQdHjjKHiOTTZkjJ0_g==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.holzerlaw.com<\/u><\/a>,\u202fand upon request from the firm. Holzer &amp; Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.\u202f<\/p>\n<p align=\"justify\">CONTACT:<br \/>Corey Holzer, Esq.<br \/>(888) 508-6832 (toll-free)<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qm8tKnp3GDM_shC4dxF90zzH33E-EeNAFT3vm7-rg_xN9T9ED49x79icOOrYzhBbnKg6cgMOt7pQkvfvG4BSFQ==\" rel=\"nofollow noopener\" target=\"_blank\">cholzer@holzerlaw.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5OTE0NSM1NTAyMTUwIzIxODA3Njc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDk4ZjJhNDAtZjczNS00NzU0LWE4YjEtMWU3YTZmYWY2MWFlLTExOTIzMzY=\/tiny\/Holzer-Holzer.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ATLANTA, March 30, 2023 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether Fulcrum Therapeutics, Inc. (\u201cFulcrum\u201d\u202for the \u201cCompany\u201d) (NASDAQ: FULC) complied with federal securities laws. On February 24, 2023, Fulcrum announced that \u201con February 23, 2023, the U.S. Food and Drug Administration (FDA) verbally informed the company that it has issued a full clinical hold regarding the Investigational New Drug (IND) application for FTX-6058.\u201d Following this announcement, the price of the Company\u2019s stock dropped. If you purchased Fulcrum stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey Holzer, Esq. at\u202fcholzer@holzerlaw.com\u202for Joshua Karr, Esq. at\u202fjkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at https:\/\/holzerlaw.com\/case\/fulcrum\/ to discuss your legal rights. Holzer &amp; Holzer, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Investigation of Fulcrum Therapeutics, Inc. (FULC) Announced by Holzer &amp; Holzer, LLC&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-744022","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Investigation of Fulcrum Therapeutics, Inc. (FULC) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investigation of Fulcrum Therapeutics, Inc. (FULC) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATLANTA, March 30, 2023 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether Fulcrum Therapeutics, Inc. (\u201cFulcrum\u201d\u202for the \u201cCompany\u201d) (NASDAQ: FULC) complied with federal securities laws. On February 24, 2023, Fulcrum announced that \u201con February 23, 2023, the U.S. Food and Drug Administration (FDA) verbally informed the company that it has issued a full clinical hold regarding the Investigational New Drug (IND) application for FTX-6058.\u201d Following this announcement, the price of the Company\u2019s stock dropped. If you purchased Fulcrum stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey Holzer, Esq. at\u202fcholzer@holzerlaw.com\u202for Joshua Karr, Esq. at\u202fjkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at https:\/\/holzerlaw.com\/case\/fulcrum\/ to discuss your legal rights. Holzer &amp; Holzer, &hellip; Continue reading &quot;Investigation of Fulcrum Therapeutics, Inc. (FULC) Announced by Holzer &amp; Holzer, LLC&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-30T19:41:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5OTE0NSM1NTAyMTUwIzIxODA3Njc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Investigation of Fulcrum Therapeutics, Inc. (FULC) Announced by Holzer &amp; Holzer, LLC\",\"datePublished\":\"2023-03-30T19:41:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\\\/\"},\"wordCount\":251,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5OTE0NSM1NTAyMTUwIzIxODA3Njc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\\\/\",\"name\":\"Investigation of Fulcrum Therapeutics, Inc. (FULC) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5OTE0NSM1NTAyMTUwIzIxODA3Njc=\",\"datePublished\":\"2023-03-30T19:41:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5OTE0NSM1NTAyMTUwIzIxODA3Njc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5OTE0NSM1NTAyMTUwIzIxODA3Njc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investigation of Fulcrum Therapeutics, Inc. (FULC) Announced by Holzer &amp; Holzer, LLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investigation of Fulcrum Therapeutics, Inc. (FULC) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/","og_locale":"en_US","og_type":"article","og_title":"Investigation of Fulcrum Therapeutics, Inc. (FULC) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk","og_description":"ATLANTA, March 30, 2023 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether Fulcrum Therapeutics, Inc. (\u201cFulcrum\u201d\u202for the \u201cCompany\u201d) (NASDAQ: FULC) complied with federal securities laws. On February 24, 2023, Fulcrum announced that \u201con February 23, 2023, the U.S. Food and Drug Administration (FDA) verbally informed the company that it has issued a full clinical hold regarding the Investigational New Drug (IND) application for FTX-6058.\u201d Following this announcement, the price of the Company\u2019s stock dropped. If you purchased Fulcrum stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey Holzer, Esq. at\u202fcholzer@holzerlaw.com\u202for Joshua Karr, Esq. at\u202fjkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at https:\/\/holzerlaw.com\/case\/fulcrum\/ to discuss your legal rights. Holzer &amp; Holzer, &hellip; Continue reading \"Investigation of Fulcrum Therapeutics, Inc. (FULC) Announced by Holzer &amp; Holzer, LLC\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-30T19:41:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5OTE0NSM1NTAyMTUwIzIxODA3Njc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Investigation of Fulcrum Therapeutics, Inc. (FULC) Announced by Holzer &amp; Holzer, LLC","datePublished":"2023-03-30T19:41:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/"},"wordCount":251,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5OTE0NSM1NTAyMTUwIzIxODA3Njc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/","name":"Investigation of Fulcrum Therapeutics, Inc. (FULC) Announced by Holzer &amp; Holzer, LLC - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5OTE0NSM1NTAyMTUwIzIxODA3Njc=","datePublished":"2023-03-30T19:41:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5OTE0NSM1NTAyMTUwIzIxODA3Njc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5OTE0NSM1NTAyMTUwIzIxODA3Njc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-of-fulcrum-therapeutics-inc-fulc-announced-by-holzer-holzer-llc-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Investigation of Fulcrum Therapeutics, Inc. (FULC) Announced by Holzer &amp; Holzer, LLC"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/744022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=744022"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/744022\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=744022"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=744022"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=744022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}